We aimed at evaluating whether b-glucans could improve low-density lipoprotein (LDL) cholesterol levels and/or glycemic control in patients with myasthenia gravis (MG), in whom statins usually have muscle-related side effects. Fifty-nine MG patients participated in the study and received a daily dietary supplement of 3 g of b-glucans during 8 weeks. Body mass index (BMI) and blood sample analysis of lipid and glucose status were performed before and after 8 weeks intake of b-glucans. In the 52 patients who completed the study, there was a significant reduction in total cholesterol, LDL, ApoA1 and ApoB (all Po0.003). However, glycemic control and BMI were unaltered. The present study indicates that 8 weeks daily intake of 3 g of b-glucans significantly reduces total cholesterol, LDL, ApoA1 and ApoB in MG patients. b-glucans may therefore be of value in improving lipid status in MG patients, without the muscle-related side effects accompanied by statins.
INTRODUCTION
Low-density lipoprotein cholesterol (LDL-C) is of major importance for development of cardiovascular events through atherosclerosis 1 and thus, lowering LDL-C significantly reduces the risk for cardiovascular events through statins. 2 Myasthenia gravis (MG) is an autoimmune neuromuscular disorder that causes skeletal muscle fatigue, and in MG patients, statins may cause aggravated muscle fatigue. 3 b-glucans are natural ingredients in oat and 3 g daily is proclaimed to reduce LDL-C levels by 5-6%. 4 In addition, b-glucans improve long-term glycemic control in diabetes patients. 5 Chronic corticosteroid treatment in many MG patients increases blood glucose levels and the risk of developing type II diabetes. Further, MG patients are limited regarding physical activity and hence a dietary supplement that reduces cholesterol without side effects would be a welcome to avoid development of cardiovascular disease.
MATERIALS AND METHODS

Study design
This was a prospective, non-placebo-controlled study, where each patient was his/her own control. The primary hypothesis was that b-glucans reduce LDL-C in MG patients and the secondary hypothesis was that b-glucans improve glycemic control. All subjects gave their written informed consent to participate in the study, which was approved by the Regional Ethical Review Board of Uppsala (Dnr: 2011/35).
Subjects. Fifty-nine MG patients (28 women and 31 men) aged 30-90 years were recruited from Uppsala University Hospital and surrounding hospitals. Exclusion criteria were pre-existing supplement with b-glucans or gluten intolerance. Statistical analysis. Two-sided one-sample t-tests were performed based on within-patient change over time. The hypothesis for each test was that the mean value of the difference from baseline (day 0) to the followup at 8 weeks equals 0 (no difference). The significance level was Po0.05.
RESULTS
Medical history and baseline status MG disease duration was 0-48 years (mean 10 years) among the 59 included patients. In total, 81% had elevated BMI, out of which 50% had BMI425-30, 19% had BMI430-35 and 12% had BMI435. Median baseline BMI was 28.5. Eighteen (31%) patients had hypertension and ten (17%) patients had a diagnosed hypercholesterolemia, out of which nine (90%) patients had statin treatment. Diabetes was noted in nine (15%) patients and insulin injections were required in seven cases.
Approximately 81% of the patients had elevated total cholesterolX5 mmol/l and 70% of patients had LDLX3 mmol/l (Table 1) . Furthermore, 44% had elevated TGsX1.8 mmol/l and 27% had an ApoBX1.2 g/l. Regarding glycemic status, 20% of patients had an elevated HbA1c (IFCC) value446 mmol/mol and 40% had morning blood glucose46 mmol/l. Ten percentage of patients were non-fasting, which may have contributed to slightly false high levels.
Improved LDL-C but unchanged glycemic control after b-glucan treatment Fifty-two patients completed the study. Total cholesterol was reduced by 0.4 mmol/l, on average a 5.5% reduction (P ¼ 0.0004). LDL-C was reduced by 0.3 mmol/l (7.5%; P ¼ 0.0002); with a slightly higher reduction in patients with baseline LDL-CX3 mmol/l. LDL-C was reduced in 35 patients and slightly increased in 14 patients at follow-up. LDL-C was equally reduced by 0.3 mmol/l in patients with and without diabetes, as well as in patients with normal or elevated BMI. Further, ApoA1 was reduced by 0.08 g/l, (4.7%; P ¼ 0.0028) and ApoB was reduced by 0.07 g/l (6.1%; P ¼ 0.0008). There was no significant reduction of TGs (P ¼ 0.75), HDL-C (P ¼ 0.18) or ApoB/ApoA1 ratio (P ¼ 0.25). Body weight, and consequently BMI, was unchanged (P ¼ 0.20). Mean HbA1c changed from 42.9-43.1 mmol/mol, indicating unaltered glycemic control (P ¼ 0.77).
DISCUSSION
Lowering LDL-C reduces the risk of coronary heart disease, 6 and b-glucans have been shown to reduce LDL-C. 7, 4 MG patients cannot perform physical exercise as healthy subjects, which could contribute to the observed obesity and high LDL-C levels. Musculoskeletal statin-associated side effects are the most prevalent and statins may also aggravate MG fatigue. 3, 8 Our study confirmed that 3 g of daily b-glucan supplementation significantly reduced total cholesterol by 5.5%, LDL-C by 7.5% and ApoB by 6.1% in only 8 weeks. The importance of this combined reduction of LDL-C and ApoB was highlighted in a recent meta-analysis, where decreased ApoB improved coronary heart disease prediction when added to LDL-C reduction. 9 Interestingly, though, the statin trials were done over several years compared with 8 weeks with b-glucans.
Although a previous study showed that 4 g of b-glucans reduce postprandial blood glucose levels in healthy subjects, 10 3 g of b-glucans did not significantly reduce HbA1c or fasting blood glucose. Our low number of diabetic patients could have made it difficult to prove a reduction of 'normal' HbA1c levels and additionally we did not determine postprandial blood glucose levels.
In conclusion, 3 g of b-glucans significantly reduce total cholesterol, LDL-C and ApoB after 8 weeks of supplementation in MG patients. b-glucans may therefore serve as a dietary supplement in reducing LDL-C in these patients, without the muscle-related side effects that often accompany statins. 
